Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2025-12-25 @ 7:03 PM
Study NCT ID:
NCT03534804
Status:
COMPLETED
Last Update Posted:
2024-11-26
First Post:
2018-05-11
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma
Sponsor:
University of Utah
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-09-18
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-04-15
Completion Date Type:
ACTUAL
First Submit Date:
2018-05-11
First Submit QC Date:
None
Study First Post Date:
2018-05-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-08-02
Results First Submit QC Date:
None
Results First Post Date:
2024-11-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-04
Last Update Post Date:
2024-11-26
Last Update Post Date Type:
ACTUAL